Reports Q2 revenue $629.7M, consensus $615.34M. “I’m pleased with the quarterly results, demonstrating our team’s strong performance as we continue to execute our long-term growth strategy, deliver on NuVasive integration plans, launch meaningful new products into the market and drive strong financial performance,” said Dan Scavilla, CEO. “I believe the potential for Globus has never been greater, as we redefine surgery with procedural solutions built around enabling technology.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- GMED Upcoming Earnings Report: What to Expect?
- Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
- Globus Medical receives FDA 510k clearance for ExcelsiusFlex, ACTIFY
- Globus Medical price target raised to $78 from $63 at Truist
- Globus Medical price target raised to $71 from $67 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue